Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 64 articles: HTML format

Single Articles

September 2026
1. NEAMTIU L, Callister MEJ, Crosbie P, Lam S, et al
   IARC Perspective on Lung Cancer Screening.
   N Engl J Med. 2026 Sep 24. doi: 10.1056/NEJMsb2608211.
   PubMed    
   
   
   
2. ZHAO Y, Liu H, Meng X, Liu Z, et al
   Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
   N Engl J Med. 2026 Sep 12. doi: 10.1056/NEJMoa2610229.
   PubMed     Abstract available
   
   
   
3. HEYMACH JV
   Zongertinib in HER2-Mutant Non-Small-Cell Lung Cancer. Reply.
   N Engl J Med. 2026;395:1038.
   PubMed    
   
   
   
4. PEDABALLE KS
   Zongertinib in HER2-Mutant Non-Small-Cell Lung Cancer.
   N Engl J Med. 2026;395:1037-1038.
   PubMed    
   
   
   
5. CALLISTER MEJ, Silvestri GA
   Pulmonary Nodules.
   N Engl J Med. 2026;395:894-905.
   PubMed     Abstract available
   
   
   
6. ARBOUR KC, Punekar S, Luo J, Johnson M, et al
   Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
   N Engl J Med. 2026;395:882-893.
   PubMed     Abstract available
   
   
   August 2026
7. ZHOU C, Greillier L, Liu G, John T, et al
   First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
   N Engl J Med. 2026;395:765-775.
   PubMed     Abstract available
   
   
   July 2026
8. YUE D, Huang M, Song P, Chen Y, et al
   Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
   N Engl J Med. 2026;395:151-161.
   PubMed     Abstract available
   
   
   May 2026
9. WU YL, Hochmair M, Yang Y, Yang XN, et al
   Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
   N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2602628.
   PubMed     Abstract available
   
   
   April 2026
10. HEYMACH JV, Yamamoto N, Girard N, Ruiter G, et al
    First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026 Apr 15. doi: 10.1056/NEJMoa2516969.
    PubMed     Abstract available
    
    
    March 2026
11. PARK W, Kasi A, Spira AI, Paz-Ares Rodriguez L, et al
    Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
    N Engl J Med. 2026 Mar 25. doi: 10.1056/NEJMoa2600752.
    PubMed     Abstract available
    
    
    February 2026
12. LE X, Brase JC, Bao W
    Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2026;394:622.
    PubMed    
    
    
    
13. WU L, Yu J, Liu W
    Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026;394:621-622.
    PubMed    
    
    
    January 2026
14. FANG W, Wu L, Meng X, Yao Y, et al
    Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2026;394:13-26.
    PubMed     Abstract available
    
    
    
15. JANNE PA, Planchard D, Kobayashi K, Yang JC, et al
    Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2026;394:27-38.
    PubMed     Abstract available
    
    
    November 2025
16. FORDE PM, Provencio M, Girard N
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
    N Engl J Med. 2025;393:2069-2070.
    PubMed    
    
    
    
17. LI X, Mu X
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2025;393:2068-2069.
    PubMed    
    
    
    October 2025
18. DIMOU A, Mansfield A
    EGFR-Mutated Lung Cancer - Letting the Butterfly Out of the Cocoon.
    N Engl J Med. 2025;393:1743-1745.
    PubMed    
    
    
    
19. YANG JC, Lu S, Hayashi H, Felip E, et al
    Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2025;393:1681-1693.
    PubMed     Abstract available
    
    
    
20. LE X, Kim TM, Loong HH, Prelaj A, et al
    Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2025 Oct 17. doi: 10.1056/NEJMoa2511065.
    PubMed     Abstract available
    
    
    
21. RUDIN CM, Mountzios G
    Tarlatamab in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2025;393:1348-1349.
    PubMed    
    
    
    
22. YILDIZ O, Araz M
    Tarlatamab in Small-Cell Lung Cancer.
    N Engl J Med. 2025;393:1348.
    PubMed    
    
    
    August 2025
23. CALVO V
    Redefining Lung Cancer Therapy - A Long-Awaited Shift in Strategy.
    N Engl J Med. 2025;393:809-810.
    PubMed    
    
    
    June 2025
24. LENTZ RJ, Frederick-Dyer K, Planz VB, Koyama T, et al
    Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
    N Engl J Med. 2025;392:2100-2112.
    PubMed     Abstract available
    
    
    
25. MOUNTZIOS G, Sun L, Cho BC, Demirci U, et al
    Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502099.
    PubMed     Abstract available
    
    
    
26. FORDE PM, Spicer JD, Provencio M, Mitsudomi T, et al
    Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931.
    PubMed     Abstract available
    
    
    April 2025
27. HEYMACH JV, Ruiter G, Ahn MJ, Girard N, et al
    Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2025 Apr 28. doi: 10.1056/NEJMoa2503704.
    PubMed     Abstract available
    
    
    
28. PICH O, Bernard E, Zagorulya M, Rowan A, et al
    Tumor-Infiltrating Clonal Hematopoiesis.
    N Engl J Med. 2025;392:1594-1608.
    PubMed     Abstract available
    
    
    December 2024
29. SENAN S
    Durvalumab in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;391:2386.
    PubMed    
    
    
    
30. PETRELLI F, Dottorini L, Ghidini A
    Durvalumab in Small-Cell Lung Cancer.
    N Engl J Med. 2024;391:2385-2386.
    PubMed    
    
    
    
31. RAMELLA S, Ippolito E, D'Angelillo RM
    Durvalumab in Small-Cell Lung Cancer.
    N Engl J Med. 2024;391:2385.
    PubMed    
    
    
    October 2024
32. CHO BC, Lu S, Felip E, Spira AI, et al
    Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2024;391:1486-1498.
    PubMed     Abstract available
    
    
    September 2024
33. CHENG Y, Spigel DR, Cho BC, Laktionov KK, et al
    Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
    N Engl J Med. 2024 Sep 13. doi: 10.1056/NEJMoa2404873.
    PubMed     Abstract available
    
    
    
34. WITTROCK E, Hagner MD
    Cannonball Pulmonary Lesions.
    N Engl J Med. 2024;391:844.
    PubMed    
    
    
    August 2024
35. LEIGHL NB
    Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match.
    N Engl J Med. 2024;391:652-654.
    PubMed    
    
    
    
36. LU S, Kato T, Dong X, Ahn MJ, et al
    Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
    N Engl J Med. 2024;391:585-597.
    PubMed     Abstract available
    
    
    
37. CASCONE T, Spicer JD, Provencio Pulla M
    Perioperative Nivolumab in Resectable Lung Cancer. Reply.
    N Engl J Med. 2024;391:573-574.
    PubMed    
    
    
    
38. SORSCHER S
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:573.
    PubMed    
    
    
    
39. SOBRERO S, Vaisitti F, Leo F
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:572-573.
    PubMed    
    
    
    June 2024
40. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    PubMed    
    
    
    May 2024
41. GARASSINO MC, Torri V
    Neoadjuvant or Perioperative Approach in Lung Cancer.
    N Engl J Med. 2024;390:1816-1818.
    PubMed    
    
    
    
42. CASCONE T, Awad MM, Spicer JD, He J, et al
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;390:1756-1769.
    PubMed     Abstract available
    
    
    April 2024
43. PASSARO A, Peters S
    Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
    N Engl J Med. 2024;390:1325-1327.
    PubMed    
    
    
    
44. WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al
    Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:1265-1276.
    PubMed     Abstract available
    
    
    
45. IZZEDINE H, Bouderlique E, Besse B
    Selpercatinib and Pseudo-Decreases in Kidney Function.
    N Engl J Med. 2024;390:1241-1243.
    PubMed    
    
    
    February 2024
46. ZHOU C, Agrawal T, Girard N
    VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
    N Engl J Med. 2024;390:579-580.
    PubMed    
    
    
    
47. MOIK F, Riedl JM, Ay C
    VTE with Amivantamab plus Chemotherapy in NSCLC.
    N Engl J Med. 2024;390:578-579.
    PubMed    
    
    
    
48. PLANCHARD D, Janne PA, Kobayashi K
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2024;390:478-479.
    PubMed    
    
    
    
49. VAN WAALWIJK VAN DOORN-KHOSROV, Badrising SK, Burgers S
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    N Engl J Med. 2024;390:478.
    PubMed    
    
    
    January 2024
50. HEYMACH JV, Harpole D, Reck M
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;390:287-288.
    PubMed    
    
    
    
51. HORITA N, Fujiwara Y
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:287.
    PubMed    
    
    
    
52. DRILON A, Camidge DR, Lin JJ, Kim SW, et al
    Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:118-131.
    PubMed     Abstract available
    
    
    November 2023
53. ZHOU C, Tang KJ, Cho BC, Liu B, et al
    Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
    N Engl J Med. 2023;389:2039-2051.
    PubMed     Abstract available
    
    
    
54. PLANCHARD D, Janne PA, Cheng Y, Yang JC, et al
    Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2023;389:1935-1948.
    PubMed     Abstract available
    
    
    
55. MULLIGAN L
    Selective RET Kinase Inhibitors and Lung Cancer.
    N Engl J Med. 2023;389:1913-1916.
    PubMed    
    
    
    
56. MCCANNON JB, Shepard JO, Wong AK, Thomas MF, et al
    Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.
    N Engl J Med. 2023;389:1902-1911.
    PubMed    
    
    
    
57. ZHOU C, Solomon B, Loong HH, Park K, et al
    First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
    N Engl J Med. 2023;389:1839-1850.
    PubMed     Abstract available
    
    
    
58. WU YL, Zhou Q
    Combination Therapy for EGFR-Mutated Lung Cancer.
    N Engl J Med. 2023 Nov 8. doi: 10.1056/NEJMe2311559.
    PubMed    
    
    
    October 2023
59. HEYMACH JV, Harpole D, Mitsudomi T, Taube JM, et al
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 23. doi: 10.1056/NEJMoa2304875.
    PubMed     Abstract available
    
    
    
60. AHN MJ, Cho BC, Felip E, Korantzis I, et al
    Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980.
    PubMed     Abstract available
    
    
    
61. PROVENCIO M, Massuti B, Romero A
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;389:1534-1535.
    PubMed    
    
    
    
62. VERMA S, Vincent M, Breadner D
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;389:1534.
    PubMed    
    
    
    
63. TSUBOI M, Herbst RS, Wu YL
    Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2023;389:1342.
    PubMed    
    
    
    
64. DI MAIO M
    Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023;389:1341-1342.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum